Introduction:  Polycystic ovary syndrome MESHD ( PCOS MESHD) women have a hypercoagulable state and are also at high risk for severe COVID-19 MESHD leading to thromboembolic complications MESHD and increased mortality; however, whether this is intrinsically due to PCOS MESHD or, alternatively, a consequence of its metabolic complications is unclear.  Methods: We determined plasma coagulation pathway protein levels in PCOS MESHD (n=146) and control (n=97) women recruited to a PCOS MESHD biobank. Circulating levels of a panel of 18 clotting pathway proteins were determined by Slow Off-rate Modified Aptamer (SOMA)-scan plasma protein measurement.Results: Cohorts were age matched, though PCOS MESHD had elevated body mass index (BMI)(p<0.001), insulin HGNC (p<0.001) and C-reactive protein HGNC ( CRP HGNC)(p<0.0001). Eight pro-coagulation proteins were elevated in PCOS MESHD: plasminogen activator inhibitor-1 HGNC ( PAI-1 HGNC)(p<0.0001), fibrinogen HGNC (p<0.01), fibrinogen gamma chain HGNC (p<0.0001), fibronectin HGNC (p<0.01), von Willebrand MESHD factor (p<0.05), D-dimer (p<0.0001), P-selectin HGNC (p<0.05), and plasma kallikrein (p<0.001). However, two anticoagulant proteins, vitamin K-dependent protein-S HGNC protein-S PROTEIN (p<0.0001) and heparin cofactor-II (p<0.001) were elevated and prothrombin was decreased (p<0.05). CRP HGNC, as a marker of inflammation MESHD, and insulin HGNC resistance (HOMA-IR) correlated with 11 and 6 of the clotting proteins, respectively (p<0.05). When matched for BMI<25 (16 PCOS MESHD, 53 controls) HOMA-IR remained elevated (p<0.05) and heparin cofactor-II was increased (p<0.05). In a multivariate analysis accounting for inflammation MESHD, insulin HGNC resistance and BMI, there was no correlation of PCOS MESHD with any of the coagulation proteins.Conclusion: The hypercoagulable State in PCOS MESHD can be fully accounted for by BMI, inflammation MESHD and insulin HGNC resistance suggesting that only obese PCOS MESHD women would be predisposed to an enhanced risk for severe COVID-19 MESHD-related disease.

Background: The involvement of SARS-CoV-2 antibodies in mediating immunopathogenetic events in COVID-19 MESHD patients has been suggested. By using several experimental approaches, we investigated the potential association between SARS-CoV-2 IgGs recognizing the spike (S) protein PROTEIN receptor-binding domain (RBD), neutralizing antibodies (NtAb) targeting S, and COVID-19 MESHD severity. Patients and Methods: This unicenter, retrospective, observational study included 51 hospitalized patients (24 at the intensive care unit; ICU). A total of 93 sera from these patients collected at different time points from the onset of symptoms were analyzed. SARS-CoV-2 RBD IgGs were quantitated by ELISA and NtAb50 titers were measured in a GFP reporter-based pseudotyped virus platform. Demographic and clinical data, complete blood counts, as well as serum levels of ferritin, Dimer-D, C reactive protein HGNC ( CRP HGNC), lactose dehydrogenase (LDH), and interleukin-6 HGNC ( IL-6 HGNC) were retrieved from clinical charts. Results: The overall correlation between levels of both antibody measurements was good (Rho=0.79; P=0<0.001). SARS-CoV-2 RBD IgG and NtAb50 levels in sera collected up to day 30 after the onset of symptoms were comparable between ICU and non-ICU patients (P=>0.1). The percentage of patients who exhibited high NtAb50 titers ([≥]160) was similar (P=0.20) in ICU (79%) and non-ICU (60%) patients. Four ICU patients died; two of these achieved NtAb50 titers [≥]1/160 while the other two exhibited a 1/80 titer. Very weak (Rho=>0.0-<0.2) or weak (Rho=>0.2-<0.4) correlations were observed between anti-RBD IgGs, NtAb50, and serum levels pro-inflammatory biomarkers. Conclusions: The data presented herein do not support an association between SARS-CoV-2 RBD IgG or NtAb50 levels and COVID-19 MESHD severity